F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 327 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016', provides an overview of the F. Hoffmann-La Roche Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by F. Hoffmann-La Roche Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of F. Hoffmann-La Roche Ltd.
- The report provides overview of F. Hoffmann-La Roche Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses F. Hoffmann-La Roche Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features F. Hoffmann-La Roche Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate F. Hoffmann-La Roche Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for F. Hoffmann-La Roche Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding F. Hoffmann-La Roche Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
F. Hoffmann-La Roche Ltd. Snapshot 7
F. Hoffmann-La Roche Ltd. Overview 7
Key Information 7
Key Facts 7
F. Hoffmann-La Roche Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
F. Hoffmann-La Roche Ltd. - Pipeline Review 18
Pipeline Products by Stage of Development 18
Pipeline Products - Monotherapy 19
Pipeline Products - Combination Treatment Modalities 20
Pipeline Products - Partnered Products 21
Pipeline Products - Out-Licensed Products 24
F. Hoffmann-La Roche Ltd. - Pipeline Products Glance 26
F. Hoffmann-La Roche Ltd. - Late Stage Pipeline Products 26
F. Hoffmann-La Roche Ltd. - Clinical Stage Pipeline Products 29
F. Hoffmann-La Roche Ltd. - Early Stage Pipeline Products 33
F. Hoffmann-La Roche Ltd. - Drug Profiles 36
alectinib 36
atezolizumab 38
bevacizumab 43
obinutuzumab 50
omalizumab 54
rituximab 56
alteplase 60
emicizumab 61
gantenerumab 62
idasanutlin 64
lebrikizumab 66
ocrelizumab 68
onartuzumab 70
pertuzumab 73
ranibizumab 77
tocilizumab 81
trastuzumab emtansine 85
vemurafenib 89
olesoxime 93
(danoprevir + ritonavir) 96
basimglurant 97
basmisanil 99
cobimetinib fumarate 100
codrituzumab 105
danoprevir 106
emactuzumab 108
miravirsen 109
RG-7314 111
RG-7716 112
RG-7795 113
RG-7800 115
RO-5093151 116
RO-6864018 117
TRX-1 118
vanucizumab 119
RG-6016 120
cergutuzumab amunaleukin 122
DCDS-0780A 123
lumretuzumab 124
OP-0595 126
PRX-002 127
RG-4929 128
RG-6061 129
RG-6069 131
RG-6078 132
RG-6125 133
RG-7304 135
RG-7386 136
RG-7461 137
RG-7625 138
RG-7775 139
RG-7802 140
RG-7834 141
RG-7876 142
RG-7880 143
RG-7916 144
RG-7944 145
RG-7986 147
RG-7992 148
RO-6799477 149
RO-6806127 150
RO-6836191 151
RO-6870868 152
RO-6874281 153
RO-6874813 154
RO-6889678 155
RO-7020322 156
RO-7033877 157
vismodegib 158
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases 162
CLP-257 163
GAL-F2 164
Gene Therapy to Activate Telomerase for Aplastic Anemia 165
IMA-930 166
IMA-942 167
IMA-962 168
ITMN-10534 169
ITMN-14440 170
ITMN-30162 171
Monoclonal Antibody Conjugates for Solid Tumor 172
Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections 173
Monoclonal Antibody to Inhibit VEGF-A for Ophthalmology 174
RN-486 175
RO-2959 176
RO-4938581 177
RO-5073012 178
RO-5203280 179
RO-5461111 180
RO-646198 181
RO-6839328 182
RO-6889450 183
RO-9021 184
Small Molecule 2 to Inhibit XIAP for Oncology 185
Small Molecule to Agonize GPR119 for Type II Diabetes 186
Small Molecule to Inhibit XIAP for Oncology 187
Small Molecules for Myotonic Dystrophy Type 1 188
Small Molecules to Inhibit ERG for Prostate Cancer 190
Small Molecules to Inhibit Janus Kinase 3 for Inflammation 191
Small Molecules to Inhibit PTP1B for Obesity and Diabetes 192
Small Molecules to Inhibit Viral RNA Polymerase for Influenza 193
XGFR-2 194
XGFR-4 195
Monoclonal Antibodies for Cancer 196
RG-7109 197
RO-5454948 198
RO-8994 199
Small Molecule to Activate Glycogen Synthase for Type 2 Diabetes 200
Small Molecule to Inhibit LOXL2 for Fibrosis 201
Small Molecule to Inhibit NS5B for Hepatitis C 202
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections 203
Small Molecules for Neuropsychiatric Disorders 204
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis 205
F. Hoffmann-La Roche Ltd. - Pipeline Analysis 206
F. Hoffmann-La Roche Ltd. - Pipeline Products by Target 206
F. Hoffmann-La Roche Ltd. - Pipeline Products by Route of Administration 212
F. Hoffmann-La Roche Ltd. - Pipeline Products by Molecule Type 213
F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action 214
F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates 218
F. Hoffmann-La Roche Ltd. - Dormant Projects 283
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products 288
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products 288
Discontinued Pipeline Product Profiles 290
F. Hoffmann-La Roche Ltd. - Company Statement 305
F. Hoffmann-La Roche Ltd. - Locations And Subsidiaries 307
Head Office 307
Other Locations & Subsidiaries 308
Appendix 316
Methodology 316
Coverage 316
Secondary Research 316
Primary Research 316
Expert Panel Validation 316
Contact Us 316
Disclaimer 317

List of Tables
F. Hoffmann-La Roche Ltd., Key Information 17
F. Hoffmann-La Roche Ltd., Key Facts 17
F. Hoffmann-La Roche Ltd. - Pipeline by Indication, 2016 19
F. Hoffmann-La Roche Ltd. - Pipeline by Stage of Development, 2016 28
F. Hoffmann-La Roche Ltd. - Monotherapy Products in Pipeline, 2016 29
F. Hoffmann-La Roche Ltd. - Combination Treatment Modalities in Pipeline, 2016 30
F. Hoffmann-La Roche Ltd. - Partnered Products in Pipeline, 2016 31
F. Hoffmann-La Roche Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 32
F. Hoffmann-La Roche Ltd. - Out-Licensed Products in Pipeline, 2016 34
F. Hoffmann-La Roche Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 35
F. Hoffmann-La Roche Ltd. - Pre-Registration, 2016 36
F. Hoffmann-La Roche Ltd. - Filing rejected/Withdrawn, 2016 37
F. Hoffmann-La Roche Ltd. - Phase III, 2016 38
F. Hoffmann-La Roche Ltd. - Phase II, 2016 39
F. Hoffmann-La Roche Ltd. - Phase I, 2016 41
F. Hoffmann-La Roche Ltd. - Preclinical, 2016 43
F. Hoffmann-La Roche Ltd. - Discovery, 2016 45
F. Hoffmann-La Roche Ltd. - Pipeline by Target, 2016 216
F. Hoffmann-La Roche Ltd. - Pipeline by Route of Administration, 2016 222
F. Hoffmann-La Roche Ltd. - Pipeline by Molecule Type, 2016 223
F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action, 2016 224
F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates, 2016 228
F. Hoffmann-La Roche Ltd. - Dormant Developmental Projects,2016 293
F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products, 2016 298
F. Hoffmann-La Roche Ltd., Subsidiaries 318